• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

向发展中国家引入新疫苗:障碍、机遇与复杂性。

Introducing new vaccines into developing countries: obstacles, opportunities and complexities.

作者信息

Clemens John, Jodar Luis

机构信息

International Vaccine Institute, Seoul, Korea.

出版信息

Nat Med. 2005 Apr;11(4 Suppl):S12-5. doi: 10.1038/nm1225.

DOI:10.1038/nm1225
PMID:15812482
Abstract

Infectious diseases are thought to account for nearly 25% of all deaths worldwide, and extract a disproportionate toll in developing countries. Moreover, infectious diseases are now appreciated to be major causes of the poverty and economic underdevelopment that characterize the world's poorest countries. Development and deployment of new vaccines to prevent infectious diseases in developing countries have therefore become high priorities in the global health agenda.

摘要

传染病被认为占全球所有死亡人数的近25%,并且在发展中国家造成了不成比例的沉重负担。此外,现在人们认识到传染病是世界最贫穷国家贫困和经济不发达的主要原因。因此,在发展中国家研发和推广预防传染病的新疫苗已成为全球卫生议程的高度优先事项。

相似文献

1
Introducing new vaccines into developing countries: obstacles, opportunities and complexities.向发展中国家引入新疫苗:障碍、机遇与复杂性。
Nat Med. 2005 Apr;11(4 Suppl):S12-5. doi: 10.1038/nm1225.
2
Policy analysis: an essential research tool for the introduction of vaccines in developing countries.政策分析:发展中国家引入疫苗的一项重要研究工具。
J Health Popul Nutr. 2004 Sep;22(3):331-7.
3
The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.发展中国家疫苗制造商网络(DCVMN)是确保发展中国家能够获得疫苗的关键支持者。
Vaccine. 2008 Mar 20;26(13):1611-5. doi: 10.1016/j.vaccine.2008.01.034. Epub 2008 Feb 6.
4
Drugs and vaccines around the world.世界各地的药物和疫苗。
Health Aff (Millwood). 2006 Mar-Apr;25(2):312. doi: 10.1377/hlthaff.25.2.312.
5
A real shot.
Nat Med. 2005 Apr;11(4 Suppl):S3-4. doi: 10.1038/nm1224.
6
Vaccines, global health and social equity.疫苗、全球健康与社会公平。
Immunol Cell Biol. 2009 May-Jun;87(4):274-8. doi: 10.1038/icb.2009.15. Epub 2009 Mar 24.
7
Vaccines as a global imperative--a business perspective.疫苗:全球当务之急——从商业角度看。
Health Aff (Millwood). 2011 Jun;30(6):1042-8. doi: 10.1377/hlthaff.2011.0338.
8
Vaccines and medicines for the world's poorest. Attempts of global forum for health research should be viewed with optimistic scepticism.面向世界最贫困人口的疫苗和药品。对全球卫生研究论坛的努力应持乐观的怀疑态度。
BMJ. 2000 Sep 30;321(7264):834.
9
Global vaccine project gets a shot in the arm.全球疫苗项目获得有力推动。
Nature. 2005 Jan 27;433(7024):345. doi: 10.1038/433345a.
10
Sociobehavioural research methods for the introduction of vaccines in the Diseases of the Most Impoverished Programme.在最贫困人群疾病防治项目中引入疫苗的社会行为研究方法
J Health Popul Nutr. 2004 Sep;22(3):293-303.

引用本文的文献

1
Bridging the gap in pneumonia prevention: Qualitative insights on vaccine implementation from health leaders in middle-income countries.弥合肺炎预防差距:来自中等收入国家卫生领导人对疫苗实施的定性见解。
PLOS Glob Public Health. 2025 Apr 23;5(4):e0004473. doi: 10.1371/journal.pgph.0004473. eCollection 2025.
2
Malaria vaccines: the 60-year journey of hope and final success-lessons learned and future prospects.疟疾疫苗:60年的希望之旅与最终成功——经验教训与未来展望
Trop Med Health. 2023 May 17;51(1):29. doi: 10.1186/s41182-023-00516-w.
3
Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle income countries.
新冠疫苗在低收入和中低收入国家推广后的保护效果评估。
EClinicalMedicine. 2022 Jan;43:101253. doi: 10.1016/j.eclinm.2021.101253. Epub 2021 Dec 24.
4
Towards Eradication of Malaria: Is the WHO's RTS,S/AS01 Vaccination Effective Enough?迈向消除疟疾:世界卫生组织的RTS,S/AS01疫苗是否足够有效?
Risk Manag Healthc Policy. 2021 Mar 12;14:1033-1039. doi: 10.2147/RMHP.S219294. eCollection 2021.
5
Accelerating Typhoid Conjugate Vaccine Introduction: What Can Be Learned From Prior New Vaccine Introduction Initiatives?加速伤寒结合疫苗引入:从先前新疫苗引入举措中学到了什么?
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S171-S176. doi: 10.1093/cid/ciy1118.
6
Trends in vaccine investment in middle income countries.中等收入国家疫苗投资趋势。
Hum Vaccin Immunother. 2019;15(10):2378-2385. doi: 10.1080/21645515.2019.1589287. Epub 2019 Apr 12.
7
How Are New Vaccines Prioritized in Low-Income Countries? A Case Study of Human Papilloma Virus Vaccine and Pneumococcal Conjugate Vaccine in Uganda.低收入国家如何优先考虑新疫苗?以乌干达的人乳头瘤病毒疫苗和肺炎球菌结合疫苗为例。
Int J Health Policy Manag. 2017 Dec 1;6(12):707-720. doi: 10.15171/ijhpm.2017.37.
8
Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project.模糊的捕获:合作资本主义与脑膜炎疫苗项目
Med Anthropol. 2016 Sep-Oct;35(5):419-32. doi: 10.1080/01459740.2016.1167055. Epub 2016 Mar 30.
9
Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.掌控全局的佐剂:不同类型的免疫增强剂如何驱动免疫反应的强度、类型、精细特异性和持久性
Vaccines (Basel). 2014 Apr 10;2(2):252-96. doi: 10.3390/vaccines2020252.
10
How a New Health Intervention Affects the Health Systems? Learnings from Pentavalent Vaccine Introduction in India.一项新的健康干预措施如何影响卫生系统?印度引入五价疫苗的经验教训。
Indian J Pediatr. 2016 Apr;83(4):294-9. doi: 10.1007/s12098-015-1844-x. Epub 2015 Aug 13.